{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T12:52:09Z","timestamp":1648990329521},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,7,27]],"date-time":"2014-07-27T00:00:00Z","timestamp":1406419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00347-013-2987-7","type":"journal-article","created":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T09:36:44Z","timestamp":1406281004000},"page":"709-714","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue Aspekte in der Therapie der multiplen Sklerose und Optikusneuritis"],"prefix":"10.1007","volume":"111","author":[{"given":"W.","family":"Lagr\u00e8ze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Diem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,27]]},"reference":[{"key":"2987_CR1","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1093\/brain\/aws215","volume":"135","author":"Abegg","year":"2012","unstructured":"Abegg M, Zinkernagel M, Wolf S (2012) Microcystic macular degeneration from optic neuropathy. Brain 135(Pt 12):e225","journal-title":"Brain"},{"key":"2987_CR2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajo.2004.01.040","volume":"137","author":"Beck","year":"2004","unstructured":"Beck RW, Gal RL, Bhatti MT et al (2004) Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 137:77\u201383","journal-title":"Am J Ophthalmol"},{"key":"2987_CR3","doi-asserted-by":"crossref","unstructured":"Brandt AU, Oberwahrenbrock T, Kadas EM et al (2014) Dynamic formation of macular microcysts independent of vitreous traction changes. Neurology (epub ahead of print)","DOI":"10.1212\/WNL.0000000000000545"},{"key":"2987_CR4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0093-7754(01)90216-7","volume":"28","author":"Cerami","year":"2001","unstructured":"Cerami A, Brines ML, Ghezzi P, Cerami CJ (2001) Effects of epoetin alfa on the central nervous system. Semin Oncol 28(2 Suppl 8):66\u201370","journal-title":"Semin Oncol"},{"key":"2987_CR5","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819\u20131828","journal-title":"Lancet"},{"key":"2987_CR6","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829\u20131839","journal-title":"Lancet"},{"key":"2987_CR7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G et al (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13:247\u2013256","journal-title":"Lancet Neurol"},{"key":"2987_CR8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/brain\/awh365","volume":"128","author":"Diem","year":"2005","unstructured":"Diem R, S\u00e4ttler MB, Merkler D et al (2005) Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128(Pt 2):375\u2013385","journal-title":"Brain"},{"key":"2987_CR9","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/brain\/awm203","volume":"130","author":"Ehrenreich","year":"2007","unstructured":"Ehrenreich H, Fischer B, Norra C et al (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130(Pt 10):2577\u20132588","journal-title":"Brain"},{"key":"2987_CR10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF03402029","volume":"8","author":"Ehrenreich","year":"2002","unstructured":"Ehrenreich H, Hasselblattt M, Dembrowski C et al (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495\u2013505","journal-title":"Mol Med"},{"key":"2987_CR11","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1161\/STROKEAHA.109.564872","volume":"40","author":"Ehrenreich","year":"2009","unstructured":"Ehrenreich H, Weissenborn K, Prange H et al (2009) Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40:e647\u2013e656","journal-title":"Stroke"},{"key":"2987_CR12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087\u20131097","journal-title":"N Engl J Med"},{"key":"2987_CR13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098\u20131107","journal-title":"N Engl J Med"},{"key":"2987_CR14","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/brain\/awq146","volume":"133","author":"Henderson","year":"2010","unstructured":"Henderson AP, Altmann DR, Trip AS et al (2010) A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 133:2592\u20132602","journal-title":"Brain"},{"key":"2987_CR15","unstructured":"Gold R f\u00fcr die Kommission \u201eLeitlinien\u201c der Deutschen Gesellschaft f\u00fcr Neurologie (2012) Diagnose und Therapie der Multiplen Sklerose. In: Diener HC, Weimar C (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie, 5.\u00a0Aufl. Thieme, S\u00a0441\u2013446"},{"key":"2987_CR16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.mcn.2005.04.009","volume":"29","author":"Kretz","year":"2005","unstructured":"Kretz A, Happold CJ, Marticke JK, Isenmann S (2005) Erythropoietin promotes regeneration of adult CNS neurons via Jak2\/Stat3 and PI3K\/AKT pathway activation. Mol Cell Neurosci 29(4):569\u2013579","journal-title":"Mol Cell Neurosci"},{"key":"2987_CR17","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/bjo.2008.156794","volume":"93","author":"Lagr\u00e8ze","year":"2009","unstructured":"Lagr\u00e8ze WA, Feltgen N, Bach M, Jehle T (2009) Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol 93:1667\u20131671","journal-title":"Br J Ophthalmol"},{"key":"2987_CR18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"O","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293\u20131303","journal-title":"N Engl J Med"},{"key":"2987_CR19","first-page":"727","volume":"65","author":"Optic","year":"2008","unstructured":"Optic Neuritis Study Group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65(6):727\u2013732","journal-title":"Arch Neurol"},{"key":"2987_CR20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple slerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302","journal-title":"Ann Neurol"},{"key":"2987_CR21","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1038\/sj.cdd.4401504","volume":"11","author":"S\u00e4ttler","year":"2004","unstructured":"S\u00e4ttler MB, Merkler D, Maier K et al (2004) Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 11(Suppl 2):S181\u2013S192","journal-title":"Cell Death Differ"},{"key":"2987_CR22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S1474-4422(12)70213-2","volume":"11","author":"Saidha","year":"2012","unstructured":"Saidha S, Sotirchos ES, Ibrahim MA et al (2012) Microcystic macula oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol 11(11):963\u2013972","journal-title":"Lancet Neurol"},{"key":"2987_CR23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1167\/iovs.08-2229","volume":"50","author":"Schiefer","year":"2009","unstructured":"Schiefer U, Pascual JP, Edmunds B et al (2009) Comparison of the new perimetric GATE stategy with conventional full-theshold and SITA standard strategies. Invest Ophthalmol Vis Sci 50:488\u2013494","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2987_CR24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23573","volume":"72","author":"S\u00fchs","year":"2012","unstructured":"S\u00fchs KW, Hein K, S\u00e4ttler MB et al (2012) A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 72:199\u2013210","journal-title":"Ann Neurol"},{"key":"2987_CR25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0002-9394(14)75429-7","volume":"121","author":"Trobe","year":"1996","unstructured":"Trobe JD, Beck RW, Moke PS, Cleary PA (1996) Contrast sensitivity and other vision test in the optic neuritis treatment trial. Am J Ophthalmol 121:547\u2013553","journal-title":"Am J Ophthalmol"},{"key":"2987_CR26","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/1352458511431972","volume":"8","author":"Villoslada","year":"2012","unstructured":"Villoslada P, Cuneo A, Gelfand J et al (2012) Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler 8(7):991\u2013999","journal-title":"Mult Scler"},{"key":"2987_CR27","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.ophtha.2011.11.032","volume":"119","author":"Walter","year":"2012","unstructured":"Walter SD, Ishikawa H, Galetta KM et al (2012) Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology 119(6):1250\u20131257","journal-title":"Ophthalmology"},{"key":"2987_CR28","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1167\/iovs.03-1039","volume":"45","author":"Weishaupt","year":"2004","unstructured":"Weishaupt JH, Rohde G, P\u00f6lking E et al (2004) Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 45(5):1514\u20131522","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2987_CR29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mp.2010.51","volume":"16","author":"W\u00fcstenberg","year":"2011","unstructured":"W\u00fcstenberg T, Begemann M, Bartels C et al (2011) Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol Psychiatry 16(1):26\u201336","journal-title":"Mol Psychiatry"},{"key":"2987_CR30","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1167\/iovs.06-0757","volume":"48","author":"Zhong","year":"2007","unstructured":"Zhong L, Bradley J, Schubert W et al (2007) Erythropoietin promotes survival of retinal ganglion cells in DBA\/2J glaucoma mice. Invest Ophthalmol Vis Sci 48(3):1212\u20131218","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-013-2987-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-013-2987-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-013-2987-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T05:25:02Z","timestamp":1565673902000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-013-2987-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,27]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["2987"],"URL":"https:\/\/doi.org\/10.1007\/s00347-013-2987-7","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,27]]}}}